期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

应用骨髓细胞免疫表型分析诊断和监测多发性骨髓瘤 被引量：7

Application of bone marrow cell immunophenotyping analysis in diagnosing and monitoring of multiple myeloma
原文传递
导出
摘要 用流式细胞仪分析浆细胞轻链限制性和细胞表面的一些免疫标记（如CD138、CD38、CD56、CD117）能够清楚地识别多发性骨髓瘤,监测治疗后的微小残留病.这些方法很可能成为多发性骨髓瘤重要的临床诊疗标志. Immunophenotyping with flow cytometry can clearly identify multiple myeloma cells and monitor minimal residual disease by using the characteristic of light chain restriction in plasma cells and some cell surface markers（ eg CD138, CD38, CD56, CD117 ）. This technology may provide important evidence in the diagnosis of multiple myeloma.
作者 朱平
机构地区 北京大学第一医院血液研究室
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2011年第1期2-4,共3页 Chinese Journal of Laboratory Medicine
关键词 多发性骨髓瘤 流式细胞术 免疫表型分型 肿瘤 残余 Multiple myeloma Flow cytometry Immunophenotyping Neoplasm,residual
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1陈葆国,罗文达,李伯利,郑瑞,颜卫华,石卫武.多发性骨髓瘤流式细胞术免疫表型及微量残留病研究[J].中华检验医学杂志,2011,34(1):10-14. 被引量：8
  • 2International Myeloma Working Group.Criteria for the classification of monoclonal gammopathies,multiple myeloma and related disorders:a report of the International Myeloma Working Group.Br J Haematol,2003,121:749-757.
  • 3Perfetti V,Vignarelli MC,Palladini G,et al.Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma.Immunology,2004,112:420-427.
  • 4Rawstron AC,Orfao A,Beksac M,et al.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.Haematologica,2008,93:431-438.
  • 5Gupta R,Bhaskar A,Kumar L,et al.Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma.Am J Clin Pathol,2009,132:728-732.
  • 6Lin P,Owens R,Tricot G,et al.Flow Cytometric immunophenotypic analysis of 306 cases of multiple myeloma.Am J Clin Pathol,2004,121:482-488.
  • 7Cumova J,Kovarova L,Potacova A,et al.Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting.Int J Hematol,2010,92:314-319.

二级参考文献9

  • 1Child JA,Morgan GJ,Davies FE,et al.High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma.N Engl J Med,2003,348:1875-1883.
  • 2Sun RX,Lu ZY,Wijdenes J,et al.Large scale and clinical grade purification of syndecan-1 + malignant plasma cells.J Immunol Methods,1997,205:73-79.
  • 3Rawstron AC,Orfao A,Beksac M,et al.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.Haematologica,2008,93:431-438.
  • 4Lin P,Owens R,Tricot G,et al.Flow Cytometric immunophenotypic analysis of 306 cases of multiple myeloma.Am J Clin Pathol,2004,121:482-488.
  • 5San Miguel JF,Almeida J,Mateo G,et al.Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma:a tool for comparing the efficacy of different treatment strategies and predicting outcome.Blood,2002,99:1853-1856.
  • 6Lima M,Teixeira MA,Fonseca S,et al.Immunophenotypic aberrations,DNA content,and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies.Blood Cells Mol Dis,2000,26:634-645.
  • 7Rawstron AC,Davies FE,DasGupta R,et al.Flow cytometric disease monitoring in multiple myeloma:the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.Blood,2002,100:3095-3100.
  • 8Gupta R,Bhaskar A,Kumar L,et al.Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma.Am J Clin Pathol,2009,132:728-732.
  • 9Carlo-Stella C,Guidetti A,Dinicola M,et al.CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vitro in NOD/SCID mice.Exp Hematol,2006,34:721-727.

共引文献7

同被引文献49

  • 1时杰,孙恺,朱尊民,雷平冲,刘忠文,陈玉清,郭建民,藏玉柱,杨靖,张茵.CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义[J].中华血液学杂志,2019,40(8):693-696. 被引量：9
  • 2周铁成,秦庆,杨小云,程晓东,肖鹏涛,张路,郝晓柯.免疫固定电泳在多发性骨髓瘤的临床应用[J].现代检验医学杂志,2007,22(2):68-69. 被引量：5
  • 3Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med, 2003 ;349(6) :583 - 596.
  • 4Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc,2010 ;85 (3) :232 - 238.
  • 5Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood,2006 ; 107 (9) :3489 - 3491.
  • 6Vrana JA, Gamez JD, Madden B J, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood, 2009;114 (24) :4957 - 4959.
  • 7Michael M, Kastritis E, Delimpassi S, et al. Clinical charac- teristics and outcome of primary systemic light-chain amyloidosis in Greece. Clin Lymphoma Myeloma Leuk, 2010 ; 10 ( 1 ) :56 - 61.
  • 8Cohen AD, Comenzo RL. Systemic light chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Ednc Program, 2010 ;2010:287 - 294.
  • 9Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol, 2011 ;29(14) :1924 -1933.
  • 10Dietrich S, Schonland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood, 2010; 116(4) :522 -528.

引证文献7

二级引证文献30

中华检验医学杂志
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部